Preoperative HALP and LMR as Predictors of Disease-Free Survival in Stage III Colon Cancer: Implications for Nomogram-Based Risk Assessment - Scorecard - MDSpire
Advertisement
Preoperative HALP and LMR as Predictors of Disease-Free Survival in Stage III Colon Cancer: Implications for Nomogram-Based Risk Assessment
Clinical Scorecard: Preoperative HALP and LMR as Predictors of Disease-Free Survival in Stage III Colon Cancer: Implications for Nomogram-Based Risk Assessment
At a Glance
Category
Detail
Condition
Stage III colon cancer
Key Mechanisms
Systemic inflammatory and immunonutritional biomarkers reflecting host–tumor interactions, including HALP score, SII, and LMR
Target Population
Patients with stage III colon cancer undergoing curative resection and adjuvant chemotherapy
Care Setting
Postoperative oncology care and risk-adapted management
Key Highlights
Preoperative HALP and LMR independently predict disease-free survival in stage III colon cancer patients.
A nomogram integrating inflammatory biomarkers with clinicopathological variables provides individualized recurrence risk estimation.
HALP, SII, and LMR demonstrate moderate diagnostic discrimination between malignant and benign colonic lesions.
Guideline-Based Recommendations
Diagnosis
Use preoperative HALP, SII, and LMR scores to aid differentiation between malignant and benign colonic lesions.
Assess inflammatory biomarkers as adjuncts to pathological staging for more precise prognostic stratification.
Management
Incorporate HALP and LMR values into postoperative risk assessment to guide adjuvant therapy decisions.
Utilize nomogram-based risk estimation to individualize patient management and surveillance strategies.
Monitoring & Follow-up
Monitor disease-free survival outcomes in relation to preoperative inflammatory biomarker levels.
Evaluate chemotherapy cycles alongside biomarker status to optimize treatment efficacy.
Risks
Recognize that patients with lower HALP and LMR scores have higher risk of recurrence despite standard treatment.
Consider inflammatory biomarker status when assessing prognosis to avoid underestimating recurrence risk.
Patient & Prescribing Data
Stage III colon cancer patients post-curative resection receiving standard adjuvant chemotherapy
Chemotherapy cycles and inflammatory biomarker levels (HALP and LMR) independently influence disease-free survival, supporting tailored postoperative treatment planning.
Clinical Best Practices
Restrict prognostic biomarker evaluation to homogeneous patient populations (e.g., stage III) to improve clinical relevance.
Combine inflammatory biomarkers with clinicopathological factors in predictive models for enhanced risk stratification.
Apply internally validated nomograms to support individualized postoperative management decisions.
